Profile data is unavailable for this security.
About the company
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
- Revenue in USD (TTM)0.00
- Net income in USD-32.14m
- Incorporated2007
- Employees11.00
- LocationForte Biosciences Inc3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS 75247United StatesUSA
- Phone+1 (310) 618-6994
- Fax+1 (302) 655-5049
- Websitehttps://www.fortebiorx.com/home/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lumos Pharma Inc | 1.53m | -37.13m | 19.89m | 33.00 | -- | 1.14 | -- | 13.04 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Indaptus Therapeutics Inc | 0.00 | -14.98m | 19.98m | 7.00 | -- | 2.13 | -- | -- | -1.78 | -1.78 | 0.00 | 1.10 | 0.00 | -- | -- | 0.00 | -87.86 | -66.55 | -97.46 | -81.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.68 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 20.20m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 20.23m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 20.26m | 8.00 | -- | 2.01 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 20.28m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 20.65m | 46.00 | 0.7897 | 0.4048 | 0.7791 | 0.3094 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Evaxion Biotech A/S - ADR | 73.00k | -22.13m | 21.07m | 49.00 | -- | -- | -- | 288.61 | -81.29 | -81.29 | 0.2665 | -1.25 | 0.0042 | -- | 0.091 | 1,489.80 | -126.74 | -100.11 | -183.85 | -131.65 | -- | -- | -30,308.22 | -131,560.30 | -- | -30.92 | 1.77 | -- | -- | -- | 4.51 | -- | 65.53 | -- |
| America Great Health | 219.13k | -859.20k | 21.11m | 7.00 | -- | -- | -- | 96.35 | -0.00004 | -0.00004 | 0.00001 | -0.0002 | 0.6746 | 0.0721 | 18.16 | 31,304.29 | -265.62 | -543.96 | -- | -- | 95.92 | -247.36 | -393.74 | -1,193.55 | 0.035 | -1.37 | -- | -- | 95.23 | -- | 84.35 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -32.14m | 21.13m | 11.00 | -- | 0.7358 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Biora Therapeutics Inc | 544.00k | -111.08m | 21.30m | 58.00 | -- | -- | -- | 39.16 | -7.13 | -7.12 | 0.0267 | -3.29 | 0.0143 | -- | 0.6594 | 9,379.31 | -291.43 | -122.84 | -482,965.20 | -369.01 | -- | -- | -20,419.48 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 22.00m | 91.00 | -- | 0.7984 | -- | 0.5665 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Sol Gel Technologies Ltd | 1.72m | -22.86m | 22.29m | 36.00 | -- | 0.6826 | -- | 12.96 | -0.8222 | -0.8222 | 0.0619 | 1.17 | 0.0387 | -- | 0.5154 | 47,777.78 | -51.40 | -31.60 | -57.29 | -35.49 | -- | -- | -1,329.13 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Polypid Ltd | 0.00 | -24.25m | 22.33m | 59.00 | -- | 3.13 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 22.35m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -4.87m | 22.37m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
Data as of May 24 2024. Currency figures normalised to Forte Biosciences Inc's reporting currency: US Dollar USD
54.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tybourne Capital Management (HK) Ltd.as of 31 Mar 2024 | 3.62m | 9.96% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.27m | 8.97% |
| BVF Partners LPas of 31 Mar 2024 | 2.98m | 8.19% |
| Cable Car Capital LLCas of 31 Mar 2024 | 2.03m | 5.58% |
| Fred Alger Management LLCas of 31 Mar 2024 | 1.84m | 5.05% |
| Farallon Capital Management LLCas of 31 Mar 2024 | 1.81m | 4.97% |
| BML Capital Management LLCas of 31 Mar 2024 | 1.76m | 4.84% |
| Camac Partners LLCas of 03 Jan 2024 | 1.58m | 4.33% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 642.26k | 1.77% |
| Geode Capital Management LLCas of 31 Mar 2024 | 343.43k | 0.94% |
More ▼
Data from 31 Mar 2024 - 03 May 2024Source: FactSet Research Systems Inc.
